

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Execution Date
Generex Pharmaceuticals Inc.	03/31/2008

RECEIVING PARTY DATA

Name:	Rockmore Investment Master Fund Ltd.
Street Address:	150 E. 58th Street, 28th Floor
Internal Address:	c/o Rockmore Capital, LLC
City:	New York
State/Country:	NEW YORK
Postal Code:	10155

PROPERTY NUMBERS Total: 33

Property Type	Number
Patent Number:	6312665
Patent Number:	6436367
Patent Number:	6979668
Patent Number:	7087215
Patent Number:	6432383
Patent Number:	7255102
Patent Number:	6375975
Patent Number:	6451286
Patent Number:	6221378
Patent Number:	6350458
Patent Number:	6017545
Patent Number:	6231882
Patent Number:	7070799
Patent Number:	6849263

PATENT

500506500

REEL: 020753 FRAME: 0822

OP \$1320.00 6312665

Patent Number:	6315984
Patent Number:	6350432
Patent Number:	6214375
Patent Number:	6271200
Patent Number:	6193997
Patent Number:	6290987
Patent Number:	6368855
Patent Number:	6432409
Patent Number:	7179645
Patent Number:	7205274
Patent Number:	6294153
Application Number:	11033039
Application Number:	10378371
Application Number:	11241274
Application Number:	11544530
Application Number:	11887284
Application Number:	10127347
Application Number:	10245871
Application Number:	10999208

CORRESPONDENCE DATA

Fax Number: (215)851-8383
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 215-851-8472
 Email: gmiller@eckertseamans.com, esteigerwalt@eckertseamans.com
 Correspondent Name: Gary A. Miller
 Address Line 1: 50 South 16th Street, 22nd Floor
 Address Line 2: Eckert Seamans
 Address Line 4: Philadelphia, PENNSYLVANIA 19102

ATTORNEY DOCKET NUMBER:	358594-1
NAME OF SUBMITTER:	Gary A. Miller

Total Attachments: 32

source=Patent Security Agreement#page1.tif
 source=Patent Security Agreement#page2.tif
 source=Patent Security Agreement#page3.tif
 source=Patent Security Agreement#page4.tif
 source=Patent Security Agreement#page5.tif
 source=Patent Security Agreement#page6.tif

source=Patent Security Agreement#page7.tif
source=Patent Security Agreement#page8.tif
source=Patent Security Agreement#page9.tif
source=Patent Security Agreement#page10.tif
source=Patent Security Agreement#page11.tif
source=Patent Security Agreement#page12.tif
source=Patent Security Agreement#page13.tif
source=Patent Security Agreement#page14.tif
source=Patent Security Agreement#page15.tif
source=Patent Security Agreement#page16.tif
source=Patent Security Agreement#page17.tif
source=Patent Security Agreement#page18.tif
source=Patent Security Agreement#page19.tif
source=Patent Security Agreement#page20.tif
source=Patent Security Agreement#page21.tif
source=Patent Security Agreement#page22.tif
source=Patent Security Agreement#page23.tif
source=Patent Security Agreement#page24.tif
source=Patent Security Agreement#page25.tif
source=Patent Security Agreement#page26.tif
source=Patent Security Agreement#page27.tif
source=Patent Security Agreement#page28.tif
source=Patent Security Agreement#page29.tif
source=Patent Security Agreement#page30.tif
source=Patent Security Agreement#page31.tif
source=Patent Security Agreement#page32.tif

PATENT SECURITY AGREEMENT

This PATENT SECURITY AGREEMENT (this "Patent Security Agreement") is made this 31st day of March, 2008, by the Grantors listed on the signature pages hereof (collectively, jointly and severally, "Grantors" and each individually "Grantor"), in favor of the Secured Parties under and as defined in the below-described Security Agreement.

WITNESSETH:

WHEREAS, pursuant to that certain Securities Purchase Agreement dated as of March 31, 2008 (as amended, restated, supplemented, or otherwise modified from time to time, including all schedules thereto, the "Purchase Agreement") by and among GENEREX BIOTECHNOLOGY CORPORATION, a Delaware corporation ("Parent"), and Secured Parties, Parent has agreed to sell, and Secured Parties have agreed to purchase, severally and not jointly, certain Notes and Warrants, and

WHEREAS, in order to induce the Secured Parties to purchase the Notes and Warrants as provided for in the Purchase Agreement, Grantors have executed and delivered to Secured Parties that certain Security Agreement of even date herewith (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the "Security Agreement");

WHEREAS, pursuant to the Security Agreement, Grantors are required to execute and deliver to Secured Parties this Patent Security Agreement;

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Grantors hereby agree as follows:

1. DEFINED TERMS. All capitalized terms used but not otherwise defined herein have the meanings given to them in the Security Agreement or the Purchase Agreement.

2. GRANT OF SECURITY INTEREST IN PATENT COLLATERAL. Each Grantor hereby grants to each Secured Party a continuing first priority security interest in all of such Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Patent Collateral");

(a) all of its Patents and Patent Intellectual Property Licenses to which it is a party including those referred to on Schedule I hereto;

(b) all reissues, continuations or extensions of the foregoing; and

(c) all products and proceeds of the foregoing, including any claim by such Grantor against third parties for past, present or future infringement or dilution of any Patent or any Patent licensed under any Intellectual Property License.

3. SECURITY FOR OBLIGATIONS. This Patent Security Agreement and the Security Interests created hereby secures the payment and performance of all the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Secured Obligations and would be owed by Grantors, or any of them, to Secured Parties, or any of them, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

4. SECURITY AGREEMENT. The security interests granted pursuant to this Patent Security Agreement are granted in conjunction with the security interests granted to Secured Parties pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Secured Parties with respect to their respective security interests in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.


5. AUTHORIZATION TO SUPPLEMENT. If any Grantor shall obtain rights to any new patentable inventions or become entitled to the benefit of any patent application or patent for any reissue, division, or continuation, of any patent, the provisions of this Patent Security Agreement shall automatically apply thereto. To the extent required under the Security Agreement, Grantors shall give prompt notice in writing to Secured Parties with respect to any such new patent rights. Without limiting Grantors' obligations under this Section 5, Grantors hereby authorize Secured Parties unilaterally to modify this Agreement by amending Schedule I to include any such material new patent rights of Grantors. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from any Secured Party's continuing security interest in all Collateral, whether or not listed on Schedule I.


6. COUNTERPARTS. This Patent Security Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such separate counterparts shall together constitute but one and the same instrument. In proving this Patent Security Agreement or any other Transaction Document in any judicial proceedings, it shall not be necessary to produce or account for more than one such counterpart signed by the party against whom such enforcement is sought. Any signatures delivered by a party by facsimile transmission or by e-mail transmission shall be deemed an original signature hereto.

7. CONSTRUCTION. Unless the context of this Patent Security Agreement or any other Transaction Document clearly requires otherwise, references to the plural include the singular, references to the singular include the plural, the terms "includes" and "including" are not limiting, and the term "or" has, except where otherwise indicated, the inclusive meaning represented by the phrase "and/or." The words "hereof," "herein," "hereby," "hereunder," and similar terms in this Patent Security Agreement or any other Transaction Document refer to this Patent Security Agreement or such other Transaction Document, as the case may be, as a whole and not to any particular provision of this Patent Security Agreement or such other Transaction Document, as the case may be. Section, subsection, clause, schedule, and exhibit references herein are to this Patent Security Agreement unless otherwise specified. Any reference in this Patent Security Agreement or in any other Transaction Document to any agreement, instrument, or document shall include all alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements, thereto and thereof, as applicable (subject to any restrictions on such alterations, amendments, changes, extensions, modifications, renewals, replacements, substitutions, joinders, and supplements set forth herein). Any reference herein or in any other Transaction Document to the satisfaction or repayment in full of the Secured Obligations shall mean the repayment in full in cash of all Secured Obligations other than unasserted contingent indemnification Secured Obligations. Any reference herein to any Person shall be construed to include such Person's successors and assigns. Any requirement of a writing contained herein or in any other Transaction Document shall be satisfied by the transmission of a Record and any Record so transmitted shall constitute a representation and warranty as to the accuracy and completeness of the information contained therein.


IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

GENEREX BIOTECHNOLOGY
CORPORATION, a Delaware corporation

By: 
Name: Rose C. Perri
Title: Chief Financial Officer

By: 
Name: Mark A. Fletcher
Title: Executive Vice-President, General Counsel


ANTIGEN EXPRESS, INC., a Delaware corporation

By: 
Name: Rose C. Perri
Title: Director

GENEREX PHARMACEUTICALS (USA)
LLC, a North Carolina limited liability company

By: 
Name: Mark A. Fletcher
Title: Sole Manager


GENEREX MARKETING &
DISTRIBUTION INC., an Ontario corporation

By: 
Name: Rose C. Perri
Title: Director

GENEREX PHARMACEUTICALS INC., an Ontario corporation

By: 
Name: Rose C. Perri
Title: Secretary-Treasurer

1097346 ONTARIO INC., an Ontario corporation

By: 
Name: Rose C. Perri
Title: Secretary-Treasurer

GENEREX (BERMUDA), INC., a corporation
existing pursuant to the Bermuda Companies
Act

By:  _____

Name: Mark A. Fletcher

Title: Director

Patent Registrations/Applications

Status	Grantor	Country	Patent Title	Application No.	Registration No.	Filing Date	Issue Date
Issued	Generex Pharmaceuticals Inc.	US	Aerosol Formulations for Buccal and Pulmonary Application	09/386,284	6,312,665	August 31, 1999	November 11, 2001
Issued	Generex Pharmaceuticals Inc.	US	Aerosol Formulations for Buccal and Pulmonary Application	09/251,464	6,436,367	February 17, 1999	August 20, 2002
Issued	Generex Pharmaceuticals Inc.	Australia	Aerosol Formulations for Buccal and Pulmonary Application	18518/00	760445	December 16, 1999	August 28, 2003
Issued	Generex Pharmaceuticals Inc.	Australia	Aerosol Formulations for Buccal and Pulmonary Application	46746/01	783431	December 16, 1999	July 27, 2006
Pending	Generex Pharmaceuticals Inc.	Australia	Aerosol Formulations for Buccal and Pulmonary Application	2003259466		December 16, 1999	
Pending	Generex Pharmaceuticals Inc.	Australia	Aerosol Formulations for Buccal and Pulmonary Application	2003263416		December 16, 1999	
Pending	Generex	Canada	Aerosol	2,354,148		December 16, 1999	

ATL 16,833,411v2 3/31/2008

	Pharmaceuticals Inc.		Formulations for Buccal and Pulmonary Application						
Issued	Generex Pharmaceuticals Inc.	Japan	Aerosol Formulations for Buccal and Pulmonary Application	2000-589162	3818851	December 16, 1999	June 23, 2006		
Issued	Generex Pharmaceuticals Inc.	Mexico	Aerosol Formulations for Buccal and Pulmonary Application	PA/a/2001/006380	231873	December 16, 1999	November 7, 2005		
Issued	Generex Pharmaceuticals Inc.	New Zealand	Aerosol Formulations for Buccal and Pulmonary Application	512188	512188	December 16, 1999	February 3, 2003		
Pending	Generex Pharmaceuticals Inc.	Australia	Aerosol Formulations for Buccal and Pulmonary Application	2006200276		January 23, 2006			
Issued	Generex Pharmaceuticals Inc.	Austria	Aerosol Formulations for Buccal and Pulmonary Application	99962009.9	1140019	December 16, 1999	June 25, 2003		
Issued	Generex Pharmaceuticals Inc.	Belgium	Aerosol Formulations for Buccal and Pulmonary Application	99962009.9	1140019	December 16, 1999	June 25, 2003		
Issued	Generex Pharmaceuticals	Switzerland	Aerosol Formulations for	99962009.9	1140019	December 16, 1999	June 25, 2003		

ATL 16,833,411v2 3/31/2008

Issued	Inc.		Buccal and Pulmonary Application		99962009.9	1140019	December 16, 1999	June 25, 2003
	Generex Pharmaceuticals Inc.	Cyprus	Aerosol Formulations for Buccal and Pulmonary Application					
Issued	Generex Pharmaceuticals Inc.	Germany	Aerosol Formulations for Buccal and Pulmonary Application		99962009.9	1140019	December 16, 1999	June 25, 2003
	Generex Pharmaceuticals Inc.	Denmark	Aerosol Formulations for Buccal and Pulmonary Application					
Issued	Generex Pharmaceuticals Inc.	Europe	Aerosol Formulations for Buccal and Pulmonary Application		99962009.9	1140019	December 16, 1999	June 25, 2003
	Generex Pharmaceuticals Inc.	Spain	Aerosol Formulations for Buccal and Pulmonary Application					
Issued	Generex Pharmaceuticals Inc.	Finland	Aerosol Formulations for Buccal and Pulmonary Application		99962009.9	1140019	December 16, 1999	June 25, 2003
	Generex Pharmaceuticals Inc.	France	Aerosol Formulations for Buccal and		99962009.9	1140019	December 16, 1999	June 25, 2003

ATL 16.833.411v2 3/31/2008

Issued	Generex Pharmaceuticals Inc.	United Kingdom	Pulmonary Application	99962009.9	1140019	December 16, 1999	June 25, 2003
Issued	Generex Pharmaceuticals Inc.	Greece	Aerosol Formulations for Buccal and Pulmonary Application	99962009.9	1140019	December 16, 1999	June 25, 2003
Issued	Generex Pharmaceuticals Inc.	Italy	Aerosol Formulations for Buccal and Pulmonary Application	99962009.9	1140019	December 16, 1999	June 25, 2003
Issued	Generex Pharmaceuticals Inc.	Luxembourg	Aerosol Formulations for Buccal and Pulmonary Application	99962009.9	1140019	December 16, 1999	June 25, 2003
Issued	Generex Pharmaceuticals Inc.	Monaco	Aerosol Formulations for Buccal and Pulmonary Application	99962009.9	1140019	December 16, 1999	June 25, 2003
Issued	Generex Pharmaceuticals Inc.	Netherlands	Aerosol Formulations for Buccal and Pulmonary Application	99962009.9	1140019	December 16, 1999	June 25, 2003
Issued	Generex Pharmaceuticals Inc.	Portugal	Aerosol Formulations for Buccal and Pulmonary Application	99962009.9	1140019	December 16, 1999	June 25, 2003

ATL 16.833.411v2 3/31/2008

Issued	Generex Pharmaceuticals Inc.	Sweden	Application	99962009.9	1140019	December 16, 1999	June 25, 2003
Issued	Generex Pharmaceuticals Inc.	Ireland	Aerosol Formulations for Buccal and Pulmonary Application	99962009.9	1140019	December 16, 1999	June 25, 2003
Issued	Generex Pharmaceuticals Inc.	US	Cleaning Compound for and Method of Cleaning Valves and Actuators of Metered Dose Dispensers Containing Pharmaceutical Compositions	10/320,045	6,979,668	December 16, 2002	December 27, 2005
Pending	Generex Pharmaceuticals Inc.	US	Cleaning Compound for and Method of Cleaning Valves and Actuators of Metered Dose Dispensers Containing Pharmaceutical Compositions	11/241,274		September 29, 2005	
Pending	Generex Pharmaceuticals Inc.	Canada	Composition and Method for Raising Blood Glucose Level	2,562,821		October 6, 2006	
Pending	Generex	Pakistan	Composition and	25/2007		January 10, 2007	

	Pharmaceuticals Inc.		Method for Raising Blood Glucose Level				
Pending	Generex Pharmaceuticals Inc.	New Zealand	Composition and Method for Raising Blood Glucose Level	553058		February 7, 2007	
Pending	Generex Pharmaceuticals Inc.	Australia	Composition and Method for Raising Blood Glucose Level	2007200571		February 9, 2007	
Pending	Generex Pharmaceuticals Inc.	Peru	Composition and Method for Raising Blood Glucose Level	181-2007		February 19, 2007	
Pending	Generex Pharmaceuticals Inc.	Brazil	Composition and Method for Raising Blood Glucose Level	P10702158-5		February 28, 2007	
Pending	Generex Pharmaceuticals Inc.	Federation of Russia	Composition and Method for Raising Blood Glucose Level	2007117018		May 7, 2007	
Pending	Generex Pharmaceuticals Inc.	Mexico	Composition and Method for Raising Blood Glucose Level	MX/a/2007/006203		May 23, 2007	
Pending	Generex Pharmaceuticals Inc.	US	Composition and Method for Raising Blood Glucose Level	11/544,530		October 6, 2006	
Issued	Generex Pharmaceuticals Inc.	Canada	Controlled Release Tabletting Medicine	2,181,391	2,181,391	July 17, 1996	February 15, 2000
Issued	Generex Pharmaceuticals Inc.	Australia	Drug Delivery System Using	2002301328	2002301328	September 23, 1999	November 24, 2003

Issued	Inc.		Belgium	Membrane Mimetics Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.		Switzerland	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.		Germany	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	69915347.6	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.		Denmark	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.		Europe	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.		Finland	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004

ATL 16.833.471v2 3/31/2008

Issued	Generex Pharmaceuticals Inc.	France	Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.	United Kingdom	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.	Greece	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.	Ireland	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.	Italy	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.	Luxembourg	Large Molecular Delivery System Using Aerosolized Membrane	99962011.5	1140020	December 16, 1999	March 3, 2004

Issued	Generex Pharmaceuticals Inc.	Monaco	Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.	Netherlands	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.	Sweden	Large Molecular Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	99962011.5	1140020	December 16, 1999	March 3, 2004
Issued	Generex Pharmaceuticals Inc.	New Zealand	Large Molecule Drug Delivery System Using Aerosolized Membrane-Mimetic Amphiphiles	512046	512046	December 16, 1999	August 5, 2002
Issued	Generex Pharmaceuticals Inc.	United States	Metered Dose Spray Device for Administering Pharmaceutical Agents	10/061,856	7,255,102	February 1, 2002	August 14, 2007
Pending	Generex Pharmaceuticals Inc.	Jordan	Metformin Chewing Gum	P/81/2006		March 26, 2006	
Pending	Generex	Yemen	Metformin	258/2006		March 27, 2006	

ATL 16,893,411v2 3/31/2008

	Pharmaceuticals Inc.		Chewing Gum				
Pending	Generex Pharmaceuticals Inc.	Bolivia	Metformin Chewing Gum	SP-260064		March 28, 2006	
Pending	Generex Pharmaceuticals Inc.	Chile	Metformin Chewing Gum	706-2006		March 29, 2006	
Pending	Generex Pharmaceuticals Inc.	Gulf Coop Council	Metformin Chewing Gum	GCC/p/2006/6018		March 29, 2006	
Issued	Generex Pharmaceuticals Inc.	Lebanon	Metformin Chewing Gum	7477	7477	March 29, 2006	March 29, 2006
Pending	Generex Pharmaceuticals Inc.	Peru	Metformin Chewing Gum	000346-2006		March 29, 2006	
Pending	Generex Pharmaceuticals Inc.	Paraguay	Metformin Chewing Gum	07604		March 29, 2006	
Pending	Generex Pharmaceuticals Inc.	Uruguay	Metformin Chewing Gum	29445		March 29, 2006	
Pending	Generex Pharmaceuticals Inc.	Venezuela	Metformin Chewing Gum	00642-2006		March 29, 2006	
Pending	Generex Pharmaceuticals Inc.	Armenia	Metformin Chewing Gum	PCT/CA2006/000472		March 30, 2006	
Pending	Generex Pharmaceuticals Inc.	Argentina	Metformin Chewing Gum	P060101262		March 30, 2006	
Pending	Generex Pharmaceuticals Inc.	Australia	Metformin Chewing Gum	2006228949		March 30, 2006	
Pending	Generex	Brazil	Metformin	P10611555-1		March 30, 2006	

ATL 16,633,411v2 3/31/2008

	Pharmaceuticals Inc.	Russia	Chewing Gum					
Pending	Generex Pharmaceuticals Inc.	United States	Metformin Chewing Gum	11/887,284			March 30, 2006	
Pending	Generex Pharmaceuticals Inc.	WIPO	Metformin Chewing Gum	PCT/CA2006/000 472			March 30, 2006	
Pending	Generex Pharmaceuticals Inc.	South Africa	Metformin Chewing Gum	2007/08834			March 30, 2006	
Pending	Generex Pharmaceuticals Inc.	United States	Method for Administering Insulin to the Buccal Region	10/378,371			March 3, 2003	
Issued	Generex Pharmaceuticals Inc.	United States	Method for Administering Insulin	09/538,830	6,432,383		March 30, 2000	August 13, 2002
Pending	Generex Pharmaceuticals Inc.	Canada	Methods of Administering and Enhancing Absorption of Pharmaceutical Agents	2,494,132			August 14, 2003	
Issued	Generex Pharmaceuticals Inc.	United States	Methods of Administering and Enhancing Absorption of Pharmaceutical Agents	09/519,285	6,375,975		March 6, 2000	April 23, 2002
Issued	Generex Pharmaceuticals Inc.	United States	Methods of Administering and Enhancing Absorption of Pharmaceutical Agents	09/574,504	6,451,286		May 19, 2000	September 17, 2002

ATL 16,833,411v2 3/31/2008

Issued	Generex Pharmaceuticals Inc.	United States	Methods of Administering and Enhancing Absorption of Pharmaceutical Agents	10/222,240	7,087,215	August 16, 2002	August 8, 2006
Pending	Generex Pharmaceuticals Inc.	Canada	Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application	2,410,065		May 7, 2001	
Pending	Generex Pharmaceuticals Inc.	Europe	Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application	01931281.8		May 7, 2001	
Issued	Generex Pharmaceuticals Inc.	New Zealand	Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application	522524	522524	May 7, 2001	November 3, 2003
Pending	Generex Pharmaceuticals Inc.	Japan	Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application	2001-583737		May 7, 2001	
Issued	Generex Pharmaceuticals Inc.	Mexico	Micellar Pharmaceutical Compositions for Buccal and Pulmonary	PA/a/2002/011436	237746	May 7, 2001	June 14, 2006

Issued	Generex Pharmaceuticals Inc.	United States	Application	09/386,285	6,221,378	August 31, 1999	April 24, 2001
Issued	Generex Pharmaceuticals Inc.	United States	Mixed Micellar Delivery System and Method of Preparation	09/543,988	6,350,458	April 6, 2000	February 26, 2002
Issued	Generex Pharmaceuticals Inc.	United States	Mixed Micellar Delivery System and Method of Preparation	09/021,114	6,017,545	February 10, 1998	January 25, 2000
Issued	Generex Pharmaceuticals Inc.	United States	Mixed Micellar Delivery System and Method of Preparation	09/216,733	6,231,882	December 21, 1998	May 15, 2001
Issued	Generex Pharmaceuticals Inc.	United States	Mixed Micellar Delivery System and Method of Preparation	09/538,829	7,070,799	March 30, 2000	July 4, 2006
Issued	Generex Pharmaceuticals Inc.	Austria	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	Belgium	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	Switzerland	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	Germany	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007

ATL 16,833,411v2 3/31/2008

Issued	Generex Pharmaceuticals Inc.	Denmark	Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	Europe	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	Spain	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	France	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	United Kingdom	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	Italy	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	Netherlands	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	Portugal	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007
Issued	Generex Pharmaceuticals Inc.	Sweden	Mixed Micellar Delivery System and Method of Preparation	99904638.6	1,053,011	February 5, 1999	November 14, 2007

ATL 16,633,411v2 3/31/2008

Issued	Generex Pharmaceuticals Inc.	Canada	Preparation	2,229,286	2,229,286	February 10, 1998	July 26, 2005
Pending	Generex Pharmaceuticals Inc.	Brazil	Mixed Micellar Delivery System and Method of Preparation	PI9804295-5		October 27, 1998	
Pending	Generex Pharmaceuticals Inc.	Ecuador	Mixed Micellar Delivery System and Method of Preparation	SP-98-2663		September 10, 1998	
Issued	Generex Pharmaceuticals Inc.	New Zealand	Mixed Micellar Delivery System and Method of Preparation	506024	506024	February 5, 1999	May 13, 2002
Issued	Generex Pharmaceuticals Inc.	Mexico	Mixed Micellar Delivery System and Method of Preparation	PA/a/2000/007802	244325	February 5, 1999	March 20, 2007
Issued	Generex Pharmaceuticals Inc.	Canada	Mixed Micellar Pharmaceutical Delivery System and Method of Preparation	2,382,535	2,382,535	August 25, 2000	January 22, 2008
Issued	Generex Pharmaceuticals Inc.	Australia	Mixed Micellar Pharmaceutical Delivery System and Method of Preparation	68143/00	763251	February 5, 1999	October 30, 2003
Issued	Generex Pharmaceuticals Inc.	Australia	Mixed Micellar Pharmaceutical Delivery System and Method of Preparation	2002301424	2002301424	February 5, 1999	July 22, 2005

ATL 16,833, 4T1v2 3/31/2008

Issued	Generex Pharmaceuticals Inc.	New Zealand	Mixed Micellar Pharmaceutical Delivery System and Method of Preparation	517313	517313	August 25, 2000	September 8, 2003
Pending	Generex Pharmaceuticals Inc.	Japan	Mixed Micellar Pharmaceutical Delivery System and Method of Preparation	2000-531183		February 5, 1999	
Pending	Generex Pharmaceuticals Inc.	Japan	Mixed Micellar Pharmaceutical Delivery System and Method of Preparation	2001-519880		August 25, 2000	
Pending	Generex Pharmaceuticals Inc.	WIPO	Orally Absorbed Pharmaceutical Formulation and Method of Administration	PCT/CA2005/001 816		November 30, 2005	
Pending	Generex Pharmaceuticals Inc.	Uruguay	Orally Absorbed Pharmaceutical Formulation and Method of Administration	29905		November 8, 2006	
Pending	Generex Pharmaceuticals Inc.	Chile	Orally Absorbed Pharmaceutical Formulation and Method of Administration	3067-2006		November 10, 2006	
Pending	Generex Pharmaceuticals Inc.	Pakistan	Orally Absorbed Pharmaceutical Formulation and Method of Administration	1495/2006		November 11, 2006	
Pending	Generex	Bolivia	Orally Absorbed	SP-260305-06		November 17, 2006	

ATL 16.833.411v2 3/31/2008

	Pharmaceuticals Inc.		Pharmaceutical Formulation and Method of Administration					
Pending	Generex Pharmaceuticals Inc.	Paraguay	Orally Absorbed Pharmaceutical Formulation and Method of Administration	35725			November 17, 2006	
Pending	Generex Pharmaceuticals Inc.	Peru	Orally Absorbed Pharmaceutical Formulation and Method of Administration	001475.2006			November 20, 2006	
Pending	Generex Pharmaceuticals Inc.	Jordan	Orally Absorbed Pharmaceutical Formulation and Method of Administration	428/2006			November 26, 2006	
Pending	Generex Pharmaceuticals Inc.	Argentina	Orally Absorbed Pharmaceutical Formulation and Method of Administration	P 06 01 05216			November 27, 2006	
Issued	Generex Pharmaceuticals Inc.	Lebanon	Orally Absorbed Pharmaceutical Formulation and Method of Administration	6290	7714		November 27, 2006	November 27, 2006
Pending	Generex Pharmaceuticals Inc.	Venezuela	Orally Absorbed Pharmaceutical Formulation and Method of Administration	2735-06			November 27, 2006	
Pending	Generex Pharmaceuticals	Gulf Coop Council	Orally Absorbed Pharmaceutical	GCC/P/2006/7305			November 29, 2006	

ATL 16,833,411v2 3/31/2008

	Inc.		Formulation and Method of Administration					
Pending	Generex Pharmaceuticals Inc.	Yemen	Orally Absorbed Pharmaceutical Formulation and Method of Administration	298			November 29, 2006	
Issued	Generex Pharmaceuticals Inc.	Mexico	Pharmaceutical Compositions for Buccal and Pulmonary Application	PA/a/2002/008749	233463		February 21, 2001	January 6, 2006
Pending	Generex Pharmaceuticals Inc.	Canada	Pharmaceutical Compositions for Buccal and Pulmonary Application	2,401,942			February 21, 2001	
Pending	Generex Pharmaceuticals Inc.	Europe	Pharmaceutical Compositions for Buccal and Pulmonary Application	01919686.4			February 21, 2001	
Pending	Generex Pharmaceuticals Inc.	United Kingdom	Pharmaceutical Compositions for Buccal and Pulmonary Application	01919686.4			February 21, 2001	
Pending	Generex Pharmaceuticals Inc.	Ireland	Pharmaceutical Compositions for Buccal and Pulmonary Application	01919686.4			February 21, 2001	
Pending	Generex Pharmaceuticals Inc.	Japan	Pharmaceutical Compositions for Buccal and	2001-564738			March 21, 2001	

ATL 16,833,411v2 3/31/2008

Pending	Generex Pharmaceuticals Inc.	Brazil	Pulmonary Application	PI0313451-2	August 14, 2003	
Pending	Generex Pharmaceuticals Inc.	Canada	Pharmaceutical Compositions for Buccal Delivery of Pain Relief Medications	2,494,147	August 14, 2003	
Pending	Generex Pharmaceuticals Inc.	Ecuador	Pharmaceutical Compositions for Buccal Delivery of Pain Relief Medications	SP-05-5606 PCT	August 14, 2003	
Pending	Generex Pharmaceuticals Inc.	Europe	Pharmaceutical Compositions for Buccal Delivery of Pain Relief Medications	03787980.6	August 14, 2003	
Pending	Generex Pharmaceuticals Inc.	Hong Kong	Pharmaceutical Compositions for Buccal Delivery of Pain Relief Medications	06101118.9	August 14, 2003	
Pending	Generex Pharmaceuticals Inc.	Japan	Pharmaceutical Compositions for Buccal Delivery of Pain Relief Medications	2004-528776	August 14, 2003	
Pending	Generex Pharmaceuticals Inc.	Mexico	Pharmaceutical Compositions for Buccal Delivery of Pain Relief	PA/a/2005/001886	August 14, 2003	

ATL 16,833,411v2 3/31/2008

Pending	Generex Pharmaceuticals Inc.	New Zealand	Medications	537804		August 14, 2003	
Issued	Generex Pharmaceuticals Inc.	United States	Pharmaceutical Compositions for Buccal Delivery of Pain Relief Medications	10/222,699	6,849,263	August 16, 2002	February 1, 2005
Pending	Generex Pharmaceuticals Inc.	Yemen	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	322		July 22, 2007	
Pending	Generex Pharmaceuticals Inc.	Jordan	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	299/2007		July 22, 2007	
Issued	Generex Pharmaceuticals Inc.	Iran	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	38604939	43374	July 22, 2007	October 17, 2007
Pending	Generex Pharmaceuticals Inc.	Iraq	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	133/2007		July 24, 2007	
Pending	Generex Pharmaceuticals Inc.	Gulf Coop Council	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	GCC/P/2007/8819		August 1, 2007	

ATL 16,833,411v2 3/31/2008

Pending	Generex Pharmaceuticals Inc.	Chile	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	2209-2007		July 27, 2007	
Pending	Generex Pharmaceuticals Inc.	Pakistan	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	908/2007		July 27, 2007	
Pending	Generex Pharmaceuticals Inc.	Lebanon	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	4686		July 25, 2007	
Pending	Generex Pharmaceuticals Inc.	WIPO	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	PCT/CA2007/001 345		July 30, 2007	
Pending	Generex Pharmaceuticals Inc.	Bolivia	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	SP-270253		2007	
Pending	Generex Pharmaceuticals Inc.	Peru	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	000965-2007		July 26, 2007	
Pending	Generex Pharmaceuticals Inc.	Uruguay	Pharmaceutical Formulation, Uses of and Metered Dose Dispenser Containing Same	30515		July 31, 2007	
Pending	Generex	Argentina	Pharmaceutical	P070103368		July 30, 2007	

ATL 16,833,411v2 3/31/2008

	Pharmaceuticals Inc.		Formulation. Uses of and Metered Dose Dispenser Containing Same					
Pending	Generex Pharmaceuticals Inc.	Venezuela	Pharmaceutical Formulation. Uses of and Metered Dose Dispenser Containing Same	1646-07			August 1, 2007	
Pending	Generex Pharmaceuticals Inc.	Paraguay	Pharmaceutical Formulation. Uses of and Metered Dose Dispenser Containing Same	24274			July 27, 2007	
Issued	Generex Pharmaceuticals Inc.	United States	Pharmaceutical Solubilized in Aerosol Propellant	09/388,344	6,315,984		September 3, 1999	November 13, 2001
Issued	Generex Pharmaceuticals Inc.	United States	Pharmaceutical Solubilized in Aerosol Propellant	09/272,563	6,350,432		March 19, 1999	February 26, 2002
Issued	Generex Pharmaceuticals Inc.	Canada	Pharmaceutical Solubilized in Aerosol Propellant	2,364,610	2,364,610		March 10, 2000	December 19, 2006
Issued	Generex Pharmaceuticals Inc.	Australia	Pharmaceutical Solubilized in Aerosol Propellant	31400/00	766745		March 10, 2000	February 5, 2004
Issued	Generex Pharmaceuticals Inc.	Mexico	Pharmaceutical Solubilized in Aerosol Propellant	PA/a/2001/009466	223246		March 10, 2000	October 4, 2004
Issued	Generex Pharmaceuticals Inc.	New Zealand	Pharmaceutical Solubilized in Aerosol Propellant	514319	514319		March 10, 2000	March 3, 2003
Pending	Generex Pharmaceuticals Inc.	Japan	Pharmaceutical Solubilized in Aerosol Propellant	2000-606197			March 10, 2000	
Issued	Generex Pharmaceuticals Inc.	United States	Phospholipid	09/277,600	6,214,375		March 29, 1999	April 10, 2001

ATL 16,833,411v2 3/31/2008

	Pharmaceuticals Inc.		Formulations				
Issued	Generex Pharmaceuticals Inc.	Canada	Phospholipid Formulations	2,181,390		2,181,390	July 17, 1996 April 24, 2001
Issued	Generex Pharmaceuticals Inc.	United States	Proteinic Drug Delivery System Using Aerosolized Membrane-Mimetic	09/397,701		6,271,200	September 16, 1999 August 7, 2001
Issued	Generex Pharmaceuticals Inc.	Mexico	Proteinic Drug Delivery System Using Aerosolized Membrane Mimetic Amphiphiles	PA/a/2001/006379		230980	December 16, 1999 September 30, 2005
Issued	Generex Pharmaceuticals Inc.	United States	Proteinic Drug Delivery System Using Membrane Mimetics	09/161,447		6,193,997	September 27, 1998 February 27, 2001
Issued	Generex Pharmaceuticals Inc.	United States	Proteinic Drug Delivery System Using Membrane Mimetics	09/391,664		6,290,987	September 7, 1999 September 18, 2001
Issued	Generex Pharmaceuticals Inc.	Argentina	Proteinic Drug Delivery System Using Membrane Mimetics	P990104815		AR 023055 BI	September 24, 1999 September 28, 2007
Pending	Generex Pharmaceuticals Inc.	Brazil	Proteinic Drug Delivery System Using Membrane Mimetics	P19915761-6			September 27, 1999
Issued	Generex Pharmaceuticals Inc.	Mexico	Proteinic Drug Delivery System Using Membrane Mimetics	PA/a/2001/003156		223244	September 23, 1999 October 4, 2004

ATL 16,833,411v2 3/31/2008

Pending	Generex Pharmaceuticals Inc.	Canada	Proteinic Drug Delivery System Using Membrane Mimetics	2,383,724		March 24, 2000	
Issued	Generex Pharmaceuticals Inc.	Mexico	Proteinic Drug Delivery System Using Membrane Mimetics	PA/a/2002/002485	227555	March 24, 2000	May 2, 2005
Pending	Generex Pharmaceuticals Inc.	Japan	Proteinic Drug Delivery System Using Membrane Mimetics	2001-521297		March 24, 2000	
Issued	Generex Pharmaceuticals Inc.	Belgium	Proteinic Drug Delivery System Using Membrane Mimetics	99945793.0	1,115,381	September 23, 1999	March 21, 2007
Issued	Generex Pharmaceuticals Inc.	Germany	Proteinic Drug Delivery System Using Membrane Mimetics	99945793.0	69935602.4-08	September 23, 1999	March 21, 2007
Issued	Generex Pharmaceuticals Inc.	Denmark	Proteinic Drug Delivery System Using Membrane Mimetics	99945793.0	1,115,381	September 23, 1999	March 21, 2007
Issued	Generex Pharmaceuticals Inc.	Europe	Proteinic Drug Delivery System Using Membrane Mimetics	99945793.0	1,115,381	September 23, 1999	March 21, 2007
Issued	Generex Pharmaceuticals Inc.	Spain	Proteinic Drug Delivery System Using Membrane Mimetics	99945793.0	1,115,381	September 23, 1999	March 21, 2007
Issued	Generex Pharmaceuticals Inc.	France	Proteinic Drug Delivery System Using Membrane Mimetics	99945793.0	1,115,381	September 23, 1999	March 21, 2007

ATL 16,833,411v2 3/31/2008

Issued	Generex Pharmaceuticals Inc.	United Kingdom	Proteinic Drug Delivery System Using Membrane Mimetics	99945793.0	1,115,381	September 23, 1999	March 21, 2007
Issued	Generex Pharmaceuticals Inc.	Greece	Proteinic Drug Delivery System Using Membrane Mimetics	99945793.0	1,115,381	September 23, 1999	March 21, 2007
Issued	Generex Pharmaceuticals Inc.	Ireland	Proteinic Drug Delivery System Using Membrane Mimetics	99945793.0	1,115,381	September 23, 1999	March 21, 2007
Issued	Generex Pharmaceuticals Inc.	Italy	Proteinic Drug Delivery System Using Membrane Mimetics	99945793.0	1,115,381	September 23, 1999	March 21, 2007
Issued	Generex Pharmaceuticals Inc.	New Zealand	Proteinic Drug Delivery System Using Membrane Mimetics	517499	517499	March 24, 2000	January 7, 2003
Issued	Generex Pharmaceuticals Inc.	New Zealand	Proteinic Drug Delivery System Using Membrane Mimetics	510191	510191	September 23, 1999	January 7, 2003
Issued	Generex Pharmaceuticals Inc.	United States	Pulmonary Drug Delivery by Aerosol	09/397,102	6,294,153	September 16, 1999	September 25, 2001
Issued	Generex Pharmaceuticals Inc.	Canada	Pulmonary Drug Delivery	2,353,847	2,353,847	December 16, 1999	March 6, 2007
Issued	Generex Pharmaceuticals Inc.	Belgium	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Switzerland	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006

Issued	Generex Pharmaceuticals Inc.	Germany	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Denmark	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Europe	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Spain	Pulmonary Drug Delivery	99962010.7	2274651	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	France	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	United Kingdom	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Greece	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Ireland	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Italy	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Luxembourg	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Netherlands	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Portugal	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006

Issued	Generex Pharmaceuticals Inc.	Sweden	Pulmonary Drug Delivery	99962010.7	1,143,931	December 16, 1999	October 4, 2006
Issued	Generex Pharmaceuticals Inc.	Australia	Pulmonary Drug Delivery	18519/00	759051	December 16, 1999	July 17, 2003
Issued	Generex Pharmaceuticals Inc.	Japan	Pulmonary Drug Delivery	2000-589163	3818852	December 16, 1999	June 23, 2006
Issued	Generex Pharmaceuticals Inc.	Mexico	Pulmonary Drug Delivery	PA/a/2001/006377	229755	December 16, 1999	August 5, 2005
Issued	Generex Pharmaceuticals Inc.	New Zealand	Pulmonary Drug Delivery	512272	512272	December 16, 1999	March 31, 2003
Issued	Antigen Express, Inc.	United States	Hybrid Peptides Modulate	10/197,000	7,205,274	July 17, 2002	April 17, 2007
Issued	Antigen Express, Inc.	United States	II-Key / Antigenic Hybrid Peptide Vaccines	10/253,286	7,179,645	September 24, 2002	February 20, 2007
Issued	Antigen Express, Inc.	United States	Hybrid Peptides Modulate	09/396,813	6,432,409	September 14, 1999	August 13, 2002
Issued	Antigen Express, Inc.	United States	MHC Class II Antigen	09/205,995	6,368,855	December 4, 1998	April 9, 2002
Pending	Antigen Express, Inc.	United States	Inhibition of II Expression	10/127,347		April 22, 2002	
Pending	Antigen Express, Inc.	United States	II-Key / Antigenic Epitope Hybrid Peptide Vaccines	10/245,871		September 17, 2002	
Pending	Antigen Express, Inc.	United States	Inhibition of II Expression	10/999,208		November 29, 2004	
Pending	Antigen Express, Inc.	United States	II-Key / Antigenic Epitope Hybrid Peptide Vaccines	11/033,039		January 11, 2005	

ATL 16,833.411V2 3/31/2008